Abstract |
Eleven recurrent postmenopausal breast cancer patients with osseous or lung metastases were received fadrozole hydrochloride at a dose of 1 mg twice a day for more than 8 weeks. The median disease-free interval of these 11 patients with metastasis was 74 months. Out of 11 evaluable cases, 2 PR, 6 long-NC and 3 PD were observed. The overall response rate was 18.2% and the long-NC rate was 54.5%. The average overall duration of responses and long-NC were 567 days and 573 days, respectively. There was no adverse drug reaction. A combination therapy with fadrozole hydrochloride 2 mg daily and cyclophosphamide 100 mg orally on days 1-14 was given to 14 postmenopausal patients with recurrent breast cancer. The median disease-free interval of these 14 patients with metastasis was 33 months. There were 2 CR, 3 PR, 4 long-NC, 2 NC and 3 PD. The overall response rate and long-NC rate were 35.8% and 28.6%, respectively. The average overall duration of responses and long-NC were 700 days and 443 days, respectively. The adverse drug reactions were anorexia (Grade 2) and neutropenia (Grade 1 and 2). These results suggested that a combination therapy with fadrozole hydrochloride and cyclophosphamide can be effective and contribute to survival time in the treatment of postmenopausal breast cancer.
|
Authors | M Kanzaki, Y Nakaya, K Kojima, H Toda, S Tobayama, H Machida, M Ohba |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 26
Issue 7
Pg. 959-65
(Jun 1999)
ISSN: 0385-0684 [Print] Japan |
PMID | 10396324
(Publication Type: Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Cyclophosphamide
- Fadrozole
|
Topics |
- Aged
- Antineoplastic Agents, Hormonal
(administration & dosage, therapeutic use)
- Bone Neoplasms
(drug therapy, secondary)
- Breast Neoplasms
(drug therapy, pathology)
- Cyclophosphamide
(administration & dosage)
- Drug Administration Schedule
- Drug Evaluation
- Fadrozole
(administration & dosage, therapeutic use)
- Female
- Humans
- Lung Neoplasms
(drug therapy, secondary)
- Middle Aged
- Postmenopause
- Survival Analysis
|